Jessie J found to have fluid on her lungs
The 37-year-old pop star - who underwent surgery for breast cancer six weeks ago - has revealed via social media that she's been readmitted to hospital and told that she has an infection.
Jessie said on Instagram: "6 weeks post surgery and I was back in the same ward I was after my surgery. Not expected or planned.
"I had and still have symptoms that pointed towards a blood clot on the lung. IT IS NOT A BLOOD CLOT THANK GOD.
"They ran a lot tests, which ended up showing I have an infection (still trying to figure out what) and a little fluid on my lungs.
"Finding it hard to breathe in, but I discharged myself last night (I hate being in hospital) and will continue the investigation as an outpatient. (sic)"
In a separate post, Jessie admitted that her recovery has been a mental and physical challenge for her.
The chart-topping singer wrote on the photo-sharing platform: "I know many people who will have gone through this or similar may or may not agree with me on this or not, and that's OK.
"But I know for me, the true hard journey of this whole thing physically was the day I went into surgery. The recovering physically is far from quick or easy, and mentally it's been the most challenging time for me.
"Especially as a Mum with a toddler and being unable to be the mother I usually am.
"And having to change the plans for my career for this year has been frustrating after working so hard to get to the point and excited to do it all. But it's life. I know that.
"And don't get me wrong, getting the all clear was an is incredible, but that result didn't speed up or make the recovery from the surgery any easier physically. (sic)"
Jessie also revealed that she's struggling to slow down amid her recovery.
She said: "That slow pace has been a hard reality to accept tbh. I love moving and working and being up and active but I can't be right now, and that's what it is. (sic)"
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Swinney praises Olympic champion Hoy's cancer work after Bute House meeting
Scottish First Minister John Swinney has praised the work done by Sir Chris Hoy to raise awareness of prostate cancer following a meeting at Bute House. The champion cyclist, along with his wife Lady Sarra Hoy, charities and clinicians, met with the First Minister and Health Secretary to discuss how best to tackle prostate cancer on Friday. Sir Chris announced his terminal diagnosis last year and has since urged governments to change their guidelines on the condition, pushing for GPs to contact those in at-risk groups to get tested. Speaking after the meeting, the First Minister said: 'I am extremely grateful to Sir Chris Hoy, Lady Sarra Hoy and all those who shared their valuable insights about how we can work together to better raise awareness and understanding of prostate cancer in Scotland. 'Since the news of his diagnosis last year, Sir Chris has shown tremendous leadership and courage in his campaigning. 'It is a deeply personal issue, but his commitment to helping others is remarkably brave and deservedly recognised. 'We know that the earlier cancer is diagnosed the easier it is to treat, and even cure, which is why the efforts of Sir Chris and others to raise awareness are so valuable. 'I join with a great many others in offering my very best wishes to the Hoy family, and to all families facing the challenges of cancer.' The Olympic champion reiterated his calls for men to get tested if they are worried. 'I welcomed the opportunity to meet with the First Minister, the Health Secretary, doctors and charity leaders so we could talk about our shared commitment to raising awareness and understanding of prostate cancer,' he said. 'I would particularly like to thank the other guests who joined me in talking about their personal experiences. 'Knowing some of the common symptoms of prostate cancer can save lives. These include needing to urinate more often than normal, difficulty urinating or the appearance of blood when you do. 'It is especially important for black men and those who have a family history of prostate cancer to familiarise themselves with the symptoms, but I would encourage anyone with concerns to contact their GP practice for advice as soon as they can.' Since his diagnosis, Sir Chris has focused on raising awareness of prostate cancer and is due to host a major fundraising cycling event in Glasgow in September. Laura Kerby, chief executive officer of Prostate Cancer UK, said the charity was 'delighted to be working with Sir Chris Hoy and the Scottish Government'. She added: 'In the months after Sir Chris shared his story, we saw a huge increase in men using our online risk checker and the number of men in Scotland starting treatment for prostate cancer reached an all-time high. 'We're so grateful for the lifesaving impact he's making and continues to make with events like his upcoming Tour De Four cycling challenge. 'But, today, men in Scotland are still more likely to get a late prostate cancer diagnosis than anywhere else in the UK, so it's incredibly important that we do not take our feet off the pedals. 'We're grateful to the Scottish Government and First Minister John Swinney for assembling such a talented group of experts and leaders in this space today to continue the vital work to change this unacceptable situation.' Alison Wright, chief executive officer of Prostate Scotland, said the meeting was an 'important first conversation'. 'We hope it leads to ongoing collaboration and concrete steps to close detection gaps, so no man at risk is left behind,' she said. 'Far too many men – especially those with a family history, black African or Caribbean heritage, or inherited genetic mutations – are diagnosed late because testing was only prompted by symptoms. 'We advise that clear prompts for GPs be introduced to consider PSA testing based on risk factors alone, not just symptoms. Acting early will save lives.'
Yahoo
an hour ago
- Yahoo
Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization
Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization Novel, oral candidate with first-in-class potential progresses successfully through Lilly's Phase 1 clinical trial in healthy volunteers Sitryx reintegrates SYX-1042 into portfolio of novel small molecule candidates targeting major autoimmune indications with high unmet need Oxford, UK – 8 August 2025 – Sitryx Therapeutics ('the Company'), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces that the Company has regained the rights to its itaconate mimetic, SYX-1042, for the treatment of chronic autoimmune and inflammatory diseases, from Eli Lilly & Company (Lilly), due to strategic considerations and reprioritization of Lilly's pain and inflammation portfolio. In 2024 Lilly commenced a Phase 1 first-in-human study of SYX-1042, a post-translational modification modulator program for chronic autoimmune and inflammatory diseases, following a research collaboration between the two companies. That study has completed successfully. With the return to Sitryx of SYX-1042, its phase 2-ready data package and associated API, Sitryx is assessing how best to prioritize SYX-1042 for continued in-house development or potential further partnering. Iain Kilty, Chief Executive Officer of Sitryx, commented: 'Through our partner Lilly's investment in the clinical development of SYX-1042, this program has progressed significantly, delivering positive first-in-human data. We will be reviewing this clinical data alongside the robust preclinical data package to determine the optimal path forward. We thank Lilly for this collaboration and the advances we made together, progressing important research into a first-in-class candidate which we believe holds exciting potential in multiple chronic autoimmune and inflammatory diseases.' -Ends- For more information about Sitryx please contact: ICR HealthcareMary-Jane Elliott, David Daley +44 (0)20 3709 5700Sitryx@ About SitryxSitryx is a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease. The Company has a broad pipeline of novel small molecule candidates targeting major autoimmune indications with high unmet need. Its lead candidate, SYX-5219, is a potentially first-in-class PKM2 modulator in development for atopic dermatitis as a once-daily oral therapy with future development potential across multiple autoimmune diseases. Established in 2018 with seed funding from SV Health Investors, Sitryx has raised $85 million to date from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Oxford Science Enterprises, Longwood Fund, Eli Lilly and Company, and GSK. Sitryx is headquartered in Oxford, UK. For more information, please visit in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
500 Years Later, Scientists Solve Leonardo da Vinci's Human Heart Mystery
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Here's what you'll learn when you read this story: A study reveals the beginning of understanding of the trabeculae of the heart. We're still catching up with a great deal of Leonardo da Vinci's ideas, including this one. Scientists combined genetics and fractal theory to analyze these branching heart structures. This story is a collaboration with After 500 years, researchers finally understand the anatomical function of a heart feature first described by Leonardo da Vinci. To find the answer, scientists used fractal theory, MRIs, and a lot of computational elbow grease to shed light on structures called trabeculae. They found this branching, snowflaky muscle layer plays a part in the risk of heart disease. 'The inner surfaces of the human heart are covered by a complex network of muscular strands that is thought to be a remnant of embryonic development,' the researchers explain in a paper in Nature. 'The function of these trabeculae in adults and their genetic architecture are unknown. Here we investigate trabeculae using the fractal analysis in 18,096 participants of the UK Biobank.' Leonardo drew pictures of the fine, lacy, snowflake-like trabeculae after examining a heart up close and dissecting it. The artist likely noticed the tree root-like branching structure, and he theorized that the trabeculae were like the systems we use now to keep sidewalks and roads from freezing: a network for blood, in this case, that was kept warm by circulating in small vessels around the warm and vibrant heart. In studying the trabeculae, scientists were able to identify common features across different patient imagery and to begin to draw conclusions about what the structural trabeculae are doing. 'Using biomechanical simulations and observational data from human participants, we demonstrate that trabecular morphology is an important determinant of cardiac performance,' for example, meaning certain trabecular structures meant an increased risk of cardiovascular disease. 'We identified 16 significant loci that contain genes associated with haemodynamic phenotypes and regulation of cytoskeletal arborization,' the researchers explain. By studying the genome as well as trabeculae of their tens of thousands of subjects, they began to pinpoint places in the genome that spoke to how trabeculae are able to form and function—with implications about the way other body cells form and behave as well. (Arborization is just what it sounds like: the technical term for branching, like a tree.) Fractal analysis colors everything from mapmaking to botany to telecomms: anytime a major 'trunk' branches into smaller and smaller areas until it has photographed the whole country, like Google Maps, or covered the entire Earth landmass with high-speed internet. In this case, the trabeculae branch into smaller and smaller threads, and the nature of the fractal network is where many of the clues lie. 'Only the combination of genetics, clinical research, and bioengineering led us to discover the unexpected role of myocardial trabeculae in the function of the adult heart,' researcher Hannah Meyer said in a statement. The researchers say this is also just a first step toward a more complex understanding of the trabeculae. Get the Issue Get the Issue Get the Issue Get the Issue Get the Issue Get the Issue Get the IssueGet the Issue Get the Issue You Might Also Like The Do's and Don'ts of Using Painter's Tape The Best Portable BBQ Grills for Cooking Anywhere Can a Smart Watch Prolong Your Life? Solve the daily Crossword
